|[February 26, 2014]
bluebird bio to Present at the Cowen and Company Health Care Conference
CAMBRIDGE, Mass. --(Business Wire)--
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present
at the Cowen and Company 34th Annual Health Care Conference
to be held March 2 - 5, 2014 at the Boston Marriott Copley Place Hotel,
Boston, MA. Nick Leschly, Chief bluebird, will provide an overview of
the company at the conference on Tuesday, March 4, 2014 at 8:00 AM (ET).
To access a simultaneous webcast of Mr. Leschly's overview via the
internet, log on to the "Calendar of Events" section on the Investor and
Media page of the bluebird bio's website at http://investor.bluebirdbio.com.
Please connect to the website at least ten minutes prior to the start of
the presentation to ensure adequate time for a reliable connection and
any software download that may be necessary for the webcast.
A replay of the webcasts will be available on bluebird bio's website for
ninety days following the conference. The investor presentation will be
available for download in PDF format immediately following the
presentation in the "Calendar of Events" section of the Investor and
Media page of the bluebird bio's website at http://investor.buebirdbio.com.
About bluebird bio, Inc.
bluebird bio is a clinical-stage company committed to developing
potentially transformative gene therapies for severe genetic and orphan
diseases. bluebird bio has two clinical-stage programs in development.
The most advanced product candidate, Lenti-D, is in a recently-initiated
phase 2/3 study for the treatment of childhood cerebral
adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder
affecting young boys. The next most advanced product candidate,
LentiGlobin, is currently in a phase 1/2 study in France for the
treatment of beta-thalassemia major and severe sickle cell disease. A
second phase 1/2 study with LentiGlobin in the United States has been
initiated for the treatment of beta-thalassemia major.
bluebird bio also has an early-stage chimeric antigen receptor-modified
T cell (CAR-T) program for oncology in partnership with Celgene
bluebird bio has operations in Cambridge, Massachusetts and Paris,
France. For more information, please visit www.bluebirdbio.com
This release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the advancement of the Company's clinical studies
and the potential safety and clinical benefits of the Company's product
candidates. Any forward-looking statements in this press release
are based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk of cessation or
delay of any of the ongoing or planned clinical studies and/or our
development of our product candidates, the risk of a delay in the
enrollment of patients in the Company's clinical studies, the risk that
the results of previously conducted studies involving similar product
candidates will not be repeated or observed in ongoing or future studies
involving current product candidates, the risk that our collaboration
with Celgene will not continue or will not be successful, and the risk
that any one or more of our product candidates will not be successfully
developed and commercialized. For a discussion of other risks and
uncertainties, and other important factors, any of which could cause our
actual results to differ from those contained in the forward-looking
statements, see the section entitled "Risk Factors" in our most recent
quarterly report on Form 10-Q, as well as discussions of potential
risks, uncertainties, and other important factors in our subsequent
filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release, and
bluebird bio undertakes no duty to update this information unless
required by law.
[ Back To Technology News's Homepage ]